Explore more publications!

Health Press Bhutan: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Press Bhutan.

Press releases published on March 16, 2026

Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices
Aurora Spine Corporation to Participate in the 38th Annual ROTH Conference
CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update
Cronos Group Inc. to Speak at the 38th Annual ROTH Conference
Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026
Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
MediciNova to Participate at the 38th Annual ROTH Conference
Unnatural Products Raises $45 Million Series B Financing to Advance Macrocyclic Peptide Therapeutics
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Sotera Health Appoints Kenneth D. Krause to the Board of Directors
Weight Watchers Announces Fourth Quarter and Full Year 2025 Results
Tilray Brands Enters Agreement to Acquire BrewDog’s Key U.S. Assets, Expanding Its U.S. Craft Beer Platform
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine
Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026
Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
CytomX’s Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer
NRx Pharmaceuticals (Nasdaq:NRXP) Confirms Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting
NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions